Liquid Biopsy Market
完整報告名稱與涵蓋範圍
Liquid Biopsy Market Size, Share & Trends Analysis Report, By Product (Assay Kits and Reagents, Instruments and Sample Preparation Systems, Testing Services and Laboratory Developed Tests, Software and Bioinformatics), By Biomarker (Circulating Tumor DNA, Circulating Tumor Cells, Exosomes, Extracellular Vesicles and Cell-Free RNA, Methylation, Fragmentomics and Multi-Analyte Signatures), By Application (Therapy Selection and Companion Diagnostics, Minimal Residual Disease and Recurrence Monitoring, Early Cancer Detection and Screening, Treatment Response and Resistance Monitoring), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The liquid biopsy market covers assay kits and reagents, instruments and sample preparation systems, testing services and laboratory developed tests and bioinformatics that analyse circulating tumor DNA, circulating tumor cells, extracellular vesicles and multi-analyte signatures from blood and other body fluids for therapy selection, minimal residual disease monitoring, early detection and treatment response assessment. Tissue-based genomic profiling and non-oncology cell-free DNA applications such as prenatal testing are excluded; multi-cancer early detection and companion diagnostics are addressed in greater depth in a separate InsightAce study.
Growth is driven by the entrenchment of plasma genotyping for therapy selection in lung and other cancers, by minimal residual disease testing that guides adjuvant therapy decisions and reimbursed surveillance in colorectal, breast and other cancers, by blood-based colorectal cancer screening approvals and by pharmaceutical use of liquid biopsy in trials. Technology is advancing through deeper sequencing, methylation and fragmentomic signals that improve sensitivity, tumor-informed and tumor-naive assay designs, and automation that lowers cost, while reimbursement coverage expands application by application. Regulatory oversight of laboratory developed tests, evidence requirements linking testing to outcomes, and competition between centralised services and distributable kits shape the commercial landscape.
North America leads through reimbursement and service laboratories, with Europe, China, Japan and South Korea expanding through domestic testing companies and national programs. Competition involves liquid biopsy service leaders, sequencing and diagnostic platform companies, early detection specialists and Asian genomic testing providers.
The InsightAce study includes revenue forecasts in US$ for all product, biomarker, application and end user and regional segments across 2026-2035, segment-level trend analysis, competitive positioning assessment and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Liquid Biopsy Market Snapshot
Chapter 4. Global Liquid Biopsy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Product Estimates & Trend Analysis
5.1. Product & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Product:
5.2.1. Assay Kits and Reagents
5.2.2. Instruments and Sample Preparation Systems
5.2.3. Testing Services and Laboratory Developed Tests
5.2.4. Software and Bioinformatics
Chapter 6. Market Segmentation 2: By Biomarker Estimates & Trend Analysis
6.1. Biomarker & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Biomarker:
6.2.1. Circulating Tumor DNA
6.2.2. Circulating Tumor Cells
6.2.3. Exosomes, Extracellular Vesicles and Cell-Free RNA
6.2.4. Methylation, Fragmentomics and Multi-Analyte Signatures
Chapter 7. Market Segmentation 3: By Application Estimates & Trend Analysis
7.1. Application & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
7.2.1. Therapy Selection and Companion Diagnostics
7.2.2. Minimal Residual Disease and Recurrence Monitoring
7.2.3. Early Cancer Detection and Screening
7.2.4. Treatment Response and Resistance Monitoring
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Hospitals and Cancer Centers
8.2.2. Reference and Specialty Laboratories
8.2.3. Pharmaceutical and Biotechnology Companies
Chapter 9. Liquid Biopsy Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Guardant Health, Inc.
11.2. Natera, Inc.
11.3. Roche Holding AG (Foundation Medicine)
11.4. Exact Sciences Corporation
11.5. Illumina, Inc.
11.6. GRAIL, Inc.
11.7. Tempus AI, Inc.
11.8. Bio-Rad Laboratories, Inc.
11.9. QIAGEN N.V.
11.10. Thermo Fisher Scientific Inc.
11.11. Burning Rock Biotech Limited
11.12. Freenome Holdings, Inc.
11.13. Personalis, Inc.
11.14. Menarini Silicon Biosystems
11.15. Delfi Diagnostics, Inc.
圖表清單 List of Tables & Figures
Table 1. Global Liquid Biopsy Market Revenue Forecast by Product, 2026-2035 (US$ Mn)
Figure 1. Global Liquid Biopsy Market Segmentation and Scope Overview
Table 2. Global Liquid Biopsy Market Revenue Forecast by Biomarker, 2026-2035 (US$ Mn)
Figure 2. Global Liquid Biopsy Market Share by Product, 2026 & 2035
Table 3. Global Liquid Biopsy Market Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 3. Liquid Biopsy Applications Across the Cancer Care Continuum and Their Reimbursement Status
Table 4. Global Liquid Biopsy Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Assay Sensitivity Advances from Sequencing Depth, Methylation and Fragmentomics
Table 5. Global Liquid Biopsy Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Liquid Biopsy Growth Opportunity Analysis
Table 6. North America Liquid Biopsy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Liquid Biopsy Market Participants
Table 7. Europe Liquid Biopsy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Liquid Biopsy Market
Table 8. Asia Pacific Liquid Biopsy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Centralised Service Versus Distributed Kit Models in Liquid Biopsy Commercialisation
Table 9. Strategic Developments of Leading Liquid Biopsy Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們